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Background: Lactulose is a synthetic disaccharide that can be catalyzed only by intestinal bacteria in humans and
rodents, and a large amount of hydrogen is produced by bacterial catalysis of lactulose. We previously reported
marked effects of ad libitum administration of hydrogen water on prevention of a rat model of Parkinson’s
disease (PD).
Methods: End-alveolar breath hydrogen concentrations were measured in 28 healthy subjects and 37 PD patients,
as well as in 9 rats after taking hydrogen water or lactulose. Six-hydroxydopamine (6-OHDA)-induced hemi-PD
model was stereotactically generated in rats. We compared effects of hydrogen water and lactulose on prevention
of PD. We also analyzed effects of continuous and intermittent administration of 2% hydrogen gas.
Results: Hydrogen water increased breath hydrogen concentrations from 8.6 ± 2.1 to 32.6 ± 3.3 ppm (mean and
SEM, n= 8) in 10 min in healthy subjects. Lactulose increased breath hydrogen concentrations in 86% of healthy
subjects and 59% of PD patients. Compared to monophasic hydrogen increases in 71% of healthy subjects, 32%
and 41% of PD patients showed biphasic and no increases, respectively. Lactulose also increased breath hydrogen
levels monophasically in 9 rats. Lactulose, however, marginally ameliorated 6-OHDA-induced PD in rats. Continuous
administration of 2% hydrogen gas similarly had marginal effects. On the other hand, intermittent administration of
2% hydrogen gas prevented PD in 4 of 6 rats.
Conclusions: Lack of dose responses of hydrogen and the presence of favorable effects with hydrogen water and
intermittent hydrogen gas suggest that signal modulating activities of hydrogen are likely to be instrumental in
exerting a protective effect against PD.
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Lactulose is a synthetic sugar that is made of fructose
and galactose and is not absorbed by humans or rodents
because of lack of an enzyme that catalyzes the disac-
charide. Lactulose, however, can be digested by bacteria
in the colon, and hydrogen is produced as a byproduct
[1]. A hydrogen breath test after oral administration of
lactulose is clinically applied to examine small intestinal
bacterial overgrowth, which is an underlying mechanism
of irritable bowel syndrome [2]. Lactulose is also used to
treat chronic constipation [3] and hepatic encephalop-
athy [4]. Lactulose is able to ameliorate dextran sulfate
sodium (DSS)-induced intestinal inflammation in rats
[5]. The effect is likely due to alteration of intestinal
microflora, because lactulose increases intestinal levels of
Lactobacillus [6] and Lactobacillus prevents develop-
ment of colitis in interleukin 10-deficient mice [7]. The
effect of lactulose on DSS-induced colitis can also be
ascribed to hydrogen production in the colon, because
markers of oxidative stress are reduced in the lactu-
lose-administered rats [5]. In addition, Chen and col-
leagues recently hypothesized that lactulose potentially
ameliorates cerebral infarction by producing intestinal
hydrogen [8].
We previously reported that ad libitum administration
of hydrogen water abolishes development of parkinson-
ian symptoms in a rat model of 6-hydroxydopamine
(6-OHDA)-induced Parkinson’s disease (PD) [9]. As
drinking a large amount of water is not easily accommo-
dated by PD patients, we examined whether lactulose is
able to increase breath hydrogen levels in PD patients.
We additionally tested effects of lactulose on breath
hydrogen levels and on development of 6-OHDA-
induced PD in rats. Lactulose efficiently increased breath
hydrogen levels in healthy subjects, PD patients, and
rats. Lactulose, however, marginally ameliorated develop-
ment of PD in rats. We also demonstrated that continu-
ous inhalation of hydrogen gas had marginal effects,
whereas intermittent inhalation had variable but overt
effects on prevention of PD in rats.
Materials and methods
Hydrogen preparations
We made hydrogen-saturated water (1.6 ppm or 0.8
mM) for humans using the AquelaBlue electrolysis in-
strument (Miz Co. Ltd., Fujisawa, Japan). Hydrogen
water for rats was provided by Blue Mercury Inc.
(Tokyo, Japan). Pure air (200 ml, Japan Fine Products,
Kawasaki, Japan) was equilibrated with 1 ml of hydro-
gen water, and the hydrogen concentration in the air
was measured by a gas chromatograph connected to a
semiconductor gas detector (EAGanalyzer GS-23, Sen-
sorTec Co. Ltd., Ritto, Shiga, Japan). The hydrogen con-
centrations of the AquelaBlue water were 1.4–1.6 ppmand those of the Blue Mercury water were 1.0–1.2 ppm.
We purchased lactulose from Kowa Pharmaceuticals
(Nagoya, Japan).
Human studies
The human studies were approved by the Ethical Re-
view Committee of the Nagoya University Graduate
School of Medicine. Twenty-eight healthy subjects
(38 ± 10 years; mean and SD) and 37 PD patients (59 ± 9
years) participated in the studies after appropriate
informed consent was obtained. The participants
refrained from all food, supplements, and drugs, except
water, for at least 12 hours before the studies. For stud-
ies of hydrogen water, the healthy participants rested in
a sitting position for at least 30 min and took 200 ml of
hydrogen-saturated water. End-alveolar breath was
obtained in a closed aluminum bag every 5 min for 60
min. For studies of lactulose, the healthy participants
and PD patients took 6 g lactulose in 50 ml of water,
which was the conventional dose in clinical practice.
End-alveolar breath was obtained in a closed aluminum
bag every 10 min for 180 min. The breath was immedi-
ately transferred to a gas-tight glass syringe and 1 ml
was injected into EAGanalyzer GS-23 to measure
hydrogen concentrations.
Measurement of end-alveolar hydrogen concentrations
in rats
All rat experiments were approved by the Animal Care
and Use Committee of the Nagoya University Graduate
School of Medicine. Male Sprague–Dawley rats (~300 g)
were anesthetized by an intraperitoneal injection of 330
mg/kg of chloral hydrate, and were inserted with a tra-
cheal tube following tracheotomy. Lactulose (1.3 g/kg)
was then intragastrically administrated through a gastric
tube. We aspirated 1 ml tracheal gas and immediately
injected 2 ml pure air to the trachea. The 2 ml pure
water was aspirated in two seconds and was transferred
to a closed aluminum bag containing 20 ml of pure air.
The hydrogen concentrations were measured with
EAGanalyzer GS-23.A rat model of 6-OHDA-induced Parkinson’s disease
We stereotactically infused 20 μg of 6-OHDA in 2 μl
into the right striatum of seven-week-old male Sprague–
Dawley rats (~250 g) as previously described [9]. At four
weeks after the surgery, we counted the number of
clockwise turns in 30 min after intraperitoneal adminis-
tration of 5.0 mg/kg of methamphetamine (Dainippon
Sumitomo Pharmaceuticals, Osaka, Japan) The numbers
of tyrosine hydroxylase (TH)-positive cells at the sub-
stantia nigra were counted by two blinded investigators
at four weeks [9].
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tration. For controls (n= 5) and hydrogen water (n=5),
we used the data that we reported previously [9]. To con-
firm that we could still observe prominent effects of
hydrogen water, we analyzed two additional rats with con-
trol water and two with hydrogen water. Lactulose (3.0 g)
was dissolved in 100 ml drinking water. As ~250-g rats
took ~25 ml of water per day, the rats took ~3.0 g/kg/day
of lactulose, which was 10 times higher than the conven-
tional dose of 0.3 g/kg/day for humans (18 g/day for
60 kg body weight). As the safe maximum dose of
lactulose for rats was 12 g/kg/day, the rats well toler-
ated ~3.0 g/kg/day of lactulose without overt adverse
effects including diarrhea. For continuous administration
of 2% hydrogen gas, two rats were placed in a 20-liter
air-tight chamber, which was continuously supplied with
8 liter/min of 2% hydrogen gas (Iwatani, Tokyo, Japan).
For intermittent administration of 2% hydrogen gas, the
20-liter air-tight chamber was supplied serially with 2%
hydrogen gas for 15 min and then room air for 45 min
at 8 liter/min using a time controller. The one-hour
cycle was repeated 12 times from 6 pm to 6 am to re-
capitulate the habit of drinking water once every hour
in the dark [10]. Each hydrogen administration protocol
was started 1 week before the surgery. We used
the Prizm 4.0c (GraphPad Software, La Jolla, CA) for



















































































Figure 1 Temporal profiles of end-alveolar breath hydrogen concentr
200 ml hydrogen-saturated water in 8 healthy subjects. Mean and SEM are
lactulose in 28 healthy subjects and 37 PD patients. The two curves are sta
Bonferroni post-hoc test. Mean and SEM are indicated. Three representative
(E) of breath hydrogen concentrations after taking 6 g lactulose in PD patieResults
Lactulose increased breath hydrogen in humans
We first examined end-alveolar breath hydrogen concen-
trations after taking 200 ml hydrogen-saturated water in
eight healthy subjects (Figure 1A). The hydrogen concen-
trations increased from 8.6 ± 2.1 (mean and SEM, n=8)
ppm to 32.6± 3.3 ppm in 10 min. The breath hydrogen
concentration, however, became the basal levels in 45 min.
We next examined lactulose-induced hydrogen pro-
duction in 28 healthy subjects. After taking 6 g lactulose
in 50 ml water, end-alveolar breath hydrogen concentra-
tions started to increase at 70 min and reached
38.0 ± 4.2 (mean and SEM, n= 28) ppm at 180 min (Fig-
ure 1B). The hydrogen concentrations did not reach a
plateau in the observation period of 180 min. PD
patients (n= 37) also showed similar increases of breath
hydrogen concentrations, but the average increases were
about half of the healthy subjects (P< 0.0001 by two-way
ANOVA) (Figure 1B). Inspection of temporal profiles of
hydrogen concentrations in healthy subjects and PD
patients revealed that there are three temporal patterns
(Figure 1C, D, and E). First, in 20 controls (71%) and 10
PD patients (27%), the hydrogen concentrations grad-
ually increased in a monophasic manner (Figure 1C).
Second, in 4 controls (14%) and 12 PD patients (32%),
the hydrogen concentrations increased in a biphasic
manner (Figure 1D). Third, in 4 controls (14%) and 15E
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Figure 3 Behavioral assays of 6-OHDA-infused rat model of
hemi-Parkinson’s disease. Circles represent the number of turns in
30 min after intraperitoneal injection of methamphetamine in each
rat in each group. Mean and SEM are indicated in blue. A red line
represents a putative threshold of 50 turns to conclude that
development of PD is ameliorated. Results of five rats with control
water and five with hydrogen water that we reported previously are
indicated by closed circles [9]. Two additional rats with control water
and two with hydrogen water are newly analyzed for this report
(open circles). The five groups are statistically different (P< 0.001) by
one-way ANOVA. The Dunnett’s multiple comparison post-hoc test
reveals that hydrogen water (**P< 0.01) and intermittent hydrogen
gas (*P< 0.05) are different from controls.
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remained essentially unchanged after lactulose intake
(Figure 1E). The Fisher’s exact test revealed that the tem-
poral patterns are different between healthy subjects and
PD patients (P< 0.005).
Lactulose increased breath hydrogen in rats
We next hoped to examine effects of lactulose-induced
hydrogen production on prevention of PD in rats. We
first examined whether lactulose was able to increase
breath hydrogen concentrations in rats. We intragastri-
cally administered 1.3 g/kg lactulose to ~300 g rats and
measured breath hydrogen concentrations (Figure 2).
The basal hydrogen concentrations were 23.3 ± 6.4 ppm
(mean and SEM, n= 9). The concentrations started to in-
crease at 1.5 hrs after ingestion of lactulose, and reached
124.5 ± 39.5 ppm at 6 hrs (Figure 2).
Lactulose marginally ameliorates PD in rats
We examined effects of lactulose on prevention of PD in
rats. We infused 6-OHDA in the right striatum of 7-
week-old male SD rats to make hemi-PD. Intraperitoneal
injection of methamphetamine facilitates release of syn-
aptic dopamine at the dopaminergic nerve terminals at
the striatum, which causes the rat to turn clockwise. We
counted the number of clockwise turns in 30 min at 4
weeks after the surgery, and quantified effects of hydro-
gen on prevention of development of PD (Figure 3A).
We previously reported that control water failed to pre-
vent PD development and the rats rotated 230 or more
times in 30 min, whereas hydrogen water efficiently pre-
vented development of PD and the rats rotated less than
50 times in 30 min [9]. We examined two additional rats
with control water and two with hydrogen water to con-
firm that hydrogen water still had marked effects in our






















Figure 2 Temporal profiles of end-alveolar breath hydrogen
concentrations after taking lactulose in rats. Average breath
hydrogen concentrations after intragastric administration of 1.3 g/kg
lactulose in rats. Mean and SEM of 9 rats are indicated.The PD model rats (n= 5) started to take ~3.0 g/kg/
day lactulose in drinking water one week before the sur-
gery. As 60-kg humans take a maximum of 36 g/day of
lactulose for hepatic encephalopathy, 3.0 g/kg/day is 5
times more than the amount that is used for humans.
The rats, however, showed no side effects. We confirmed
that the breath hydrogen concentrations at 4 weeks were
as high as 120.0 ± 12.6 ppm (mean and SEM, n= 3) in
the PD model rats. We counted the number of metham-
phetamine-induced clockwise turns, and found that lac-
tulose marginally ameliorated motor deficits but without
statistical significance (Figure 3A). We previously
reported that infusion of 6-OHDA reduced the number
of TH-positive cells at the substantia nigra to
40.2 ± 10.6% (mean and SD, n= 5), whereas hydrogen
water increased the ratio to 83.0 ± 10.2% [9]. Lactulose
failed to rescue the death of dopaminergic cells at the
substantia nigra and the number of TH-positive cells
remained as low as 37.0 ± 6.5% (mean and SD, n= 5),
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water.Effects of continuous and intermittent hydrogen gas on a
rat model of PD
In order to simulate lactulose administration, the PD
model rats (n= 5) were placed in a 2%-hydrogen cham-
ber one week before the surgery and stayed for four
weeks after the surgery. As we observed with lactulose,
the continuous administration of hydrogen gas margin-
ally ameliorated the number of clockwise turns but with-
out statistical significance (Figure 2A).
The differential effects of hydrogen water and continu-
ous administration of hydrogen by lactulose and hydro-
gen gas prompted us to hypothesize that intermittent
exposure to hydrogen may be essential to exert beneficial
effects for PD. We thus developed a time-controlled gas
chamber system, in which rats were serially exposed to
2% hydrogen for 15 min and then room air for the
remaining 45 min (Figure 2B). The one-hour cycle was
repeated from 6 pm to 6 am to recapitulate the rats’
habit of drinking water in the dark. Rats (n= 6) were
placed in the intermittent hydrogen gas chamber one
week before the surgery and stayed for four weeks after
the surgery. Four of the six rats favorably responded to
intermittent hydrogen administration and the numbers
of clockwise turns were decreased to less than 50,
whereas the remaining two rats showed no effects (Fig-
ure 2A). The mean and SD of the numbers of turns were
151.8 ± 216.3, which was significantly lower than those of
controls (P< 0.05).Discussion
Lactulose efficiently increased the breath hydrogen levels
in healthy subjects. Although the temporal profiles of
breath hydrogen concentrations were more variable in
PD patients, the increased hydrogen concentrations was
on average about half of that of healthy subjects. We
observed biphasic increases of breath hydrogen in 12 of
the 37 PD patients. Biphasic increases of breath hydro-
gen in a hydrogen breath test suggests small intestinal
bacterial overgrowth (SIBO), but the increases of hydro-
gen concentrations in the PD patients were less than a
commonly used threshold of 20 ppm for SIBO [2]. The
difference in temporal profiles of the breath hydrogen
concentrations between controls and PD patients, how-
ever, might be due to the difference in the ages of the
two groups (38 ± 10 years vs. 59 ± 9 years). We addition-
ally confirmed that rats also had increased breath hydro-
gen levels in a monophasic manner after taking
lactulose, which underscored a notion that intestinal bac-
teria digest lactulose and produce hydrogen in humans
and rats.In contrast to marked effects of ad libitum administra-
tion of hydrogen water on a rat model of PD, lactulose
and continuous administration of 2% hydrogen gas had
marginal effects. On the other hand, intermittent admin-
istration of 2% hydrogen gas had variable but overt
effects. When a 60-kg person drinks 1000 ml of 72%
saturated hydrogen water, the hydrogen concentration of
the body water is expected to become 0.8 mmoles x
72% / (60 kg x 60%) = 0.016 mM (2% saturation), which
is identical to the hydrogen concentration achieved by a
person staying in a 2% hydrogen chamber. Although
hydrogen in drinking water can bind to glycogen in the
liver [11], hydrogen easily dissipates in exhalation (Fig-
ure 1A). On the other hand, a person in a 2% hydrogen
chamber is exposed to 2% hydrogen for 24 hrs. The area
under the curve of hydrogen concentrations in a hydro-
gen chamber is estimated to be thus ~100 times more
than that with hydrogen water. Although a ~250-g SD
rat takes ~25 ml of water per day, which is six times
more than the amount that humans take, the rats placed
in a hydrogen chamber were still exposed to much more
amounts of hydrogen compared to the rats that took
hydrogen water. Nevertheless, we observed a prominent
protective effect against PD with hydrogen water but not
with continuous inhalation of 2% hydrogen gas or lactu-
lose. Lack of the dose response is also supported by our
observation that intermittent inhalation of 2% hydrogen
gas was more protective than continuous inhalation, al-
though the amount of hydrogen was eight times less
with intermittent hydrogen administration.
Another line of evidence that supports lack of the dose
response of hydrogen is intestinal production of hydro-
gen. Although no mammalian cells can produce hydro-
gen endogenously, hydrogen is produced by intestinal
bacteria carrying hydrogenase. Production of hydrogen
by lactulose is also achieved by these bacteria. We
humans are able to make a maximum of 12 liters of
hydrogen in our intestines [12,13]. Nevertheless, oral ad-
ministration of a small amount of hydrogen exhibits
prominent effects. In a mouse model of Concanavalin A-
induced hepatitis, elimination of intestinal bacteria by a
cocktail of antibiotics worsened the hepatitis [14]. Resti-
tution of a hydrogenase-negative strain of E. coli had no
effects, whereas that of a hydrogenase-positive stain of E.
coli ameliorated the hepatitis. This is the only report that
addressed a beneficial effect of intestinal bacteria, but
they also demonstrated that drinking hydrogen water
was more effective than restitution of hydrogenase-posi-
tive bacteria. In addition to lactulose that we tested in
our studies, we can easily increase hydrogen concentra-
tions in our bodies by an α-glucosidase inhibitor, acar-
bose [15]; milk for lactase-deficient adults that
constitute 75% of the worldwide population [16]; and an
ingredient of curry, turmeric, which enhances the bowel
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to be effective for PD.
Ohsawa and colleagues reported prominent effects of
inhaled hydrogen gas for a rat model of cerebral infarction
[18]. They demonstrated that the prominent effect of hydro-
gen is ascribed to a specific scavenging activity of hydroxyl
radicals. Effects of inhaled hydrogen gas have been reported
in 21 additional diseases, and similarly effects of drinking
hydrogen water have been reported in 18 diseases since
then [19]. Direct comparison of effects of ad libitum admin-
istration of hydrogen-saturated water and inhalation of 1%
hydrogen gas on a mouse model of cisplatin-induced
nephropathy demonstrated that the two modalities of hydro-
gen administration had similar effects [20]. A small amount
of hydrogen is likely to be sufficient to ameliorate nephropa-
thy and PD in rats, but an excessive amount of hydrogen
may somehow negate a favorable effect for PD, although no
adverse effects of hydrogen have been reported to date. Fur-
ther studies are required to prove whether the lack of dose
response is disease-specific or not.
We previously reported that hydrogen attenuates phos-
phorylation of FcERI-associated Lyn and its downstream
signaling molecules in rat RBL-2H3 mast cells [21]. We
also demonstrated that hydrogen ameliorates an immedi-
ate-type allergic reaction not by a radical-scavenging ac-
tivity but by direct modulation of signaling pathway(s).
In addition, using murine RAW264 macrophage cells,
we demonstrated that hydrogen reduces lipopolysacchar-
ide/interferon-γ-induced nitric oxide (NO) production
[22]. We found that hydrogen inhibits phosphorylation
of ASK1 and its downstream signaling molecules, p38
MAP kinase, JNK, and IκBα without affecting ROS pro-
duction by NADPH oxidase. Both studies point to a no-
tion that hydrogen is a gaseous signaling modulator. The
initial increase of hydrogen concentrations in rats drink-
ing hydrogen water was expected to be faster than that
of intermittent administration of 2% hydrogen gas, be-
cause we added 8 liter per min of 2% hydrogen gas to a
20-liter chamber. Prominent effects that we observed
with hydrogen water may be ascribed to the pulsatile in-
crease of hydrogen concentrations in rats.
Conclusions
Lactulose is a safe and tolerable source of hydrogen pro-
duction for healthy subjects and PD patients. Although lac-
tulose also increases hydrogen levels in rats, lactulose and
continuous inhalation of 2% hydrogen gas have marginal
effects on prevention of 6-OHDA-induced PD. On the
other hand, intermittent inhalation of hydrogen gas vari-
ably but overtly prevents development of PD, but not as ef-
ficiently as ad libitum administration of hydrogen water.Abbreviations
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